Printer Friendly

BIOJECT NAMES NEW CFO; DIRECTOR OF MARKETING IS ALSO ANNOUNCED IN PREPARATION FOR PRODUCT LAUNCH

 PORTLAND, Ore., Jan. 14 /PRNewswire/ -- Bioject Medical Technologies (NASDAQ: BJCT) today announced the appointment of Peggy J. Miller as vice president and chief financial officer. She will assume her responsibilities at Bioject on Feb. 1, replacing James A. Kinkade who has been with the company since 1988. Kinkade is leaving Bioject to pursue other business interests but will continue as a consultant to Bioject through the end of February.
 Miller joins Bioject from her current position as vice president for finance at Oregon Health Sciences University (OHSU). At OHSU, Miller was one of four officers responsible for the overall management and direction of the $400-million academic health sciences center.
 Prior to her association with OHSU, Miller held such positions as senior manager at Arthur Andersen & Co., vice president for finance at ALPKEM Corp. and audit manager at Price Waterhouse in Portland. ALPKEM is a medical equipment manufacturer that distributes automated blood analyzers to hospitals and clinics.
 "We appreciate the fine contribution Jim Kinkade has made to Bioject over the past four years," commented Carl Wilcox, president and chief executive officer. "We wish him well in his future endeavors and are pleased to have a highly qualified professional such as Peggy Miller join the Bioject team. Her experience will allow her to make valuable contributions as Bioject expands its operations."
 The company will begin sales of its new, needle-free injection management system, the Biojector 2000, in February. In preparation for the product launch, Bioject also announced the hiring of several professionals for key positions.
 Roger P. Jacobi will join Bioject as director of marketing on Jan. 18. He has 15 years of marketing experience with an emphasis on innovative medical products. He was most recently director of product marketing at San Jose, Calif.-based Laserscope, a developer and distributor of medical laser systems and related surgical instruments. At Laserscope he grew the company's sales from $300,000 in 1988 to $30 million in 1992. Prior to that Jacobi held several positions at General Electric Medical Systems, marketing magnetic resonance products.
 Also added to the marketing staff is Denise S. Burnham as director of pharmaceutical and clinical affairs. Prior to joining Bioject, she was a clinical pharmacist for the transplant program at Oregon Health Sciences University.
 -0- 1/14/93
 /CONTACT: Dan Zenka, APR, or Tim Justice of Bioject, 503-639-7221/
 (BJCT)


CO: Bioject Inc. ST: Oregon IN: MTC SU: PER

SW-LM -- SE004 -- 4691 01/14/93 07:50 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1993
Words:407
Previous Article:THE PRICE COMPANY ANNOUNCES FIRST QUARTER RESULTS FISCAL 1993
Next Article:MLX CORP. ANNOUNCES EXCHANGE OF PREFERRED STOCK FOR BONDS AND SENIOR DEBT AND REPLACEMENT OF ITS SUBSIDIARY SENIOR LENDER
Topics:


Related Articles
BIOJECT, KOBAYASHI SIGN DISTRIBUTION AGREEMENT FOR JAPAN
BIOJECT COMPLETES MOVE TO UNITED STATES; BIOJECT MEDICAL TECHNOLOGIES INCORPORATES IN OREGON
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT ANNOUNCES NEW VP OF SALES AND MARKETING
BIOJECT SIGNS AGREEMENTS WITH VISITING NURSE ASSOCIATIONS OF AMERICA AND WITH FORMER CHAIRMAN
Bioject Reports Improved Fiscal 1997 Performance
Bioject Signs License Agreement With Leading Japanese Pharmaceutical Company.
Bioject Announces Strategic $2.4 Million Private Placement.
Bioject CEO to Retire at Year End.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters